Keros Therapeutics (NASDAQ:KROS) Posts Earnings Results, Misses Expectations By $0.20 EPS

Keros Therapeutics (NASDAQ:KROS) posted its quarterly earnings data on Monday. The company reported ($1.45) EPS for the quarter, missing analysts’ consensus estimates of ($1.25) by ($0.20), FiscalAI reports. Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 17.04%.

Keros Therapeutics Price Performance

KROS stock traded up $0.04 during trading on Monday, hitting $10.11. The stock had a trading volume of 154,060 shares, compared to its average volume of 348,319. Keros Therapeutics has a twelve month low of $9.69 and a twelve month high of $22.55. The company’s 50-day moving average price is $10.70 and its two-hundred day moving average price is $12.65. The stock has a market capitalization of $200.10 million, a P/E ratio of -3.36 and a beta of 0.97.

Insider Buying and Selling at Keros Therapeutics

In other news, Director Julius Knowles sold 2,625 shares of Keros Therapeutics stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $10.73, for a total value of $28,166.25. Following the sale, the director directly owned 10,958 shares of the company’s stock, valued at $117,579.34. The trade was a 19.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Alpna Seth sold 2,625 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $10.72, for a total value of $28,140.00. Following the sale, the director owned 9,767 shares of the company’s stock, valued at $104,702.24. The trade was a 21.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 8,425 shares of company stock valued at $89,994 over the last quarter. 12.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Keros Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC purchased a new stake in shares of Keros Therapeutics during the first quarter worth $226,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Keros Therapeutics by 15.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,166 shares of the company’s stock worth $227,000 after buying an additional 2,982 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Keros Therapeutics by 38.3% during the first quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock worth $7,547,000 after acquiring an additional 205,022 shares during the last quarter. Creative Planning boosted its position in Keros Therapeutics by 40.2% during the second quarter. Creative Planning now owns 24,226 shares of the company’s stock worth $323,000 after acquiring an additional 6,948 shares during the last quarter. Finally, Rhumbline Advisers grew its stake in Keros Therapeutics by 16.0% during the 2nd quarter. Rhumbline Advisers now owns 51,815 shares of the company’s stock valued at $692,000 after acquiring an additional 7,146 shares in the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on KROS shares. Wall Street Zen cut shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Weiss Ratings cut shares of Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 15th. Finally, Zacks Research cut shares of Keros Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 29th. Three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Keros Therapeutics currently has an average rating of “Hold” and a consensus target price of $20.40.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.